ERBB2 and breast carcinoma: The effect of the antibody Trastuzumab was compared with that of these branched poly(ε-lysine) peptides on two breast cancer cell phenotypes: MDA-MB-231 breast cancer cells, known to have low expression of the HER2 receptor, and HER2-overexpressing SKBR3 cells [44].